Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Latest Content

India COVID-19 coronavirus by city and state

India has recorded 216,919 total confirmed cases, 6,075 deaths, 104,107 cured cases, according to the latest update released by the Union Ministry for Health and Family Welfare on Thursday evening.

Finding a cure for HIV with ViiV Healthcare and UNC-Chapel Hill

ViiV Healthcare has announced that it will renew its partnership with the University of North Carolina at Chapel Hill. The partners have been collaborating on the search for an HIV cure since 2015, bringing together academic and pharma industry skills in their quest to eliminate the virus. Abi Millar spoke to ViiV Healthcare to find out more.

Covid-19 pandemic: a deep dive into the UK’s ACCORD programme

To accelerate drugs through the early stages of clinical development and into large-scale UK studies, the UK Government’s Covid-19 Therapeutics Taskforce has created the ACCORD programme, with BerGenBio’s bemcentinib the first drug to be fast-tracked through the scheme. The company’s Mewburn Ellis patent attorney Rob Andrews explains the promise of this drug against the novel coronavirus and why taking part in the programme is beneficial for pharma companies.

Covid-19 pandemic: investigating the treatment landscape with IFPMA

It is going to take at least a year for a Covid-19 vaccine to be available; in the meantime, drugs, both novel and repurposed, could provide a quicker alternative for the pharma industry to help resolve the ongoing novel coronavirus pandemic. In a recent virtual briefing, executives from big pharma companies discussed progress to date, while noting that the industry must be exercise caution and not promise the undeliverable.

Related Treatments

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top